

Please type a plus sign (+) inside this box ?

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | |
|--|---------------------------------|--|---|--|---|--|
| Substitute for form 1449A/PTO | | | | Complete If Known | | |
| INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | | Application Number | | |
| | | | | Filing Date | | |
| | | | | First Named Inventor S. Jayaramna | | |
| | | | | Group Art Unit | | |
| | | | | Examiner Name | | |
| Sheet | 4 | of | 8 | Attorney Docket Number 795-A03-004 | | |
| U.S. PATENT DOCUMENTS | | | | | | |
| Examiner Initials | Cite No.¹ | U.S. Patent Document Number | Kind Code² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| B | EA | 2001/0029351 A1 | | Falotico et al. | 10-11-2001 | |
| | EB | 2002/0016625 A1 | | Falotico et al. | 02-07-2002 | |
| | EC | 2002/0013335 A1 | | Azrola et al. | 01-31-2002 | |
| | ED | 2002/0007215 A1 | | Falotico et al. | 01-17-2002 | |
| | EE | 2002/0007214 A1 | | Falotico et al. | 01-17-2002 | |
| | EF | 2002/0007213 A1 | | Falotico et al. | 01-17-2002 | |
| | EG | 2002/0005206 A1 | | Falotico et al. | 01-17-2002 | |
| B | EH | 2003/0086957 A1 | | Huges | 05-08-2003 | |
| | | | | | | |
| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | | | | |
| Examiner Initials | Cite No.¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T⁶ |
| B | FA | PEKKA HAYRY, Article " Genomics of Vascular Injury a Platform for Rational Drug Design" Internet Site Location, http://www.biohelsinkiconf.com/download/hayry-biotechelsinki03.pdf | | | | |
| Examiner | | Date Considered | | | | |
| [Signature] | | 9/30/04 | | | | |

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**
(use as many sheets as necessary)

(use as many sheets as necessary)

Complete If Known

Application Number

Filing Date

First Named Inventor

S. Javaramna

Group Art Unit

Examiner Name

Attorney Docket Number

795-A03-004

Sheet

4

of

8

U.S. PATENT DOCUMENTS

[illegible]

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

| | | | |
|----------------------|--------------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| B | FA | PEKKA HAYRY, Article " Genomics of Vascular Injury a Platform for Rational Drug Design" Internet Site Location, http://www.biohelsinkiconf.com/download/hayry-biotechelsinki03.pdf | |
| | | | |
| Examiner | Date Considered 9/30/04 | | |

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|---|------------------------|--------------|
| -Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor | S. Jayaraman |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 2 | of | 8 | Attorney Docket Number | 795-A03-004 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|-----------------------------|-----------------------------------|---|--|---|
| Examiner Initials | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| B | AW | 5,688,824 | | Williams | 11-18-1997 | / |
| | AX | 5,728,710 | | Luengo | 03-17-1998 | |
| | AY | 5,837,313 | | Ding et al. | 11-17-1998 | |
| | AZ | 5,891,507 | | Jayaraman | 04-06-1998 | |
| | BA | 5,997,468 | | Wolff et al. | 12-07-1999 | |
| | BB | 6,046,328 | | Schonharting et al. | 04-04-2000 | |
| | BC | 6,051,596 | | Badger | 04-18-2000 | |
| | BD | 6,071,305 | | Brown et al. | 06-06-2000 | |
| | BE | 6,129,705 | | Grantz | 10-10-2000 | |
| | BF | 6,143,037 | | Goldstein et al. | 11-07-2000 | |
| | BG | 6,153,252 | | Hossainy et al. | 11-28-2000 | |
| | BH | 6,197,781 | | Guitard et al. | 03-06-2001 | |
| | BI | 6,203,551 | | Wu | 03-20-2001 | |
| | BJ | 6,231,600 | | Zhong | 05-15-2001 | |
| | BK | 6,238,430 | | Klumb et al. | 05-29-2001 | |
| | BL | 6,239,102 | | Tiemessen | 05-29-2001 | |
| | BM | 6,239,124 | | Zenke et al. | 05-29-2001 | |
| | BN | 6,245,104 | | Alt | 06-12-2001 | |
| | BO | 6,248,127 | | Shah et al. | 06-19-2001 | |
| | B | BP | 6,251,136 | | Gurwaiya et al. | |
| BQ | | 6,254,634 | | Anderson et al. | 07-03-2001 | |

| | |
|------------------------|---------------------------------|
| Examiner: <u>J. J.</u> | Date Considered: <u>9/30/04</u> |
|------------------------|---------------------------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|---|------------------------|-------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor | |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 8 | Attorney Docket Number | 795-A03-004 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------------------|--------------------------------|--------------------------------------|--|--|---|
| Examiner Initials | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| 3 | AA | 3,903,071 | | Holmes | 09-02-1975 | / |
| | AB | 4,650,803 | | Stella et al. | 03-17-1987 | |
| | AC | 5,100,899 | | Calne | 03-31-1992 | |
| | AD | 5,212,155 | | Calne | 05-18-1993 | |
| | AE | 5,221,740 | | Hughes | 06-22-1993 | |
| | AF | 5,282,785 | | Shapland et al. | 02-01-1994 | |
| | AG | 5,283,257 | | Gregory et al. | 02-01-1994 | |
| | AH | 5,286,254 | | Shapland et al. | 02-15-1994 | |
| | AI | 5,286,731 | | Caufield et al. | 02-15-1994 | |
| | AJ | 5,288,711 | | Mitchell et al. | 02-22-1994 | |
| | AK | 5,308,847 | | Calne | 05-03-1994 | |
| | AL | 5,318,895 | | Kahn et al. | 06-07-1994 | |
| | AM | 5,403,833 | | Calne | 04-04-1995 | |
| | AN | 5,457,113 | | Cullinan et al. | 10-10-1995 | |
| | AO | 5,461,058 | | Calne | 10-24-1995 | |
| | AP | 5,496,832 | | Armstrong | 03-05-1996 | |
| | AQ | 5,508,397 | | Or et al. | 04-16-1996 | |
| | AR | 5,516,781 | | Morris et al. | 05-14-1996 | |
| | AS | 5,519,042 | | Morris et al. | 05-21-1996 | |
| | AT | 5,624,946 | | Williams | 04-29-1997 | |
| 4 | AU | 5,646,160 | | Morris et al. | 07-08-1997 | |
| | AV | 5,674,732 | | Nishida et al. | 10-07-1997 | |
| Examiner | | | | Date Considered 9/30/04 | | |

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|--------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | |
| | | Filing Date | |
| | | First Named Inventor | S. JAYARAMAN |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 5 of 8 | Attorney Docket Number | 795-A03-004 | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials ² | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuu number(s), publisher, city and/or country where published | T ² |
| B | FB | D. BUNJES, C. HARDT, M. WILLINGHOFF and, H. WAGNER, CYCLOSPORIN A MEDIATES IMMUNOSUPPRESSION OF PRIMARY CYTOTOXIC T CELL RESPONSES BY IMPAIRING THE RELEASE OF INTERLEUKIN 1 AND INTERLEUKIN 2, J. IMMUNOL. 1981, 11:657-661. | |
| | FC | J. DIJOSEPH, E. FLUHLER, J. ARMSTRONG, M. SHARR, and S. SEHGAL, THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT, TRANSPLANTATION 1996, 62:1109-1112. | |
| | FD | B. HAUSEN, K. BOEKE, G. BERRY, I. BEGARRA, L. BENET, U. CHRISTIANS and R. MORRIS, COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTS, TRANSPLANTATION 1999, 67:956-962. | |
| | FE | L. TURKA, J. DAYTON, G. SINCLAIR, C. THOMPSON, and B. MITCHELL, GUANINE RIBONUCLEOTIDE DEPLETION INHIBITS T CELL ACTIVATION, J. Clin. Invest. 1991, 87:940-948. | |
| | FF | W. SCHULER, R. SEDRANI, S. COTTENS, B. HABERLIN, M. SCHULZ, H. SCHUURMAN, G. ZENKER, H. ZERWES, and M. SCHREIBER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:36-42. | |
| | FG | H. SCHUURMAN, J. RINGERS, W. SCHULER, W. SLINGERLAND and M. JONKER, ORAL EFFICACY OF THE MACROLIDE IMMUNOSUPPRESSANT SDZ RAD AND OF CYCLOSPORINE MICROEMULSION IN CYNOMOLGUS MONKEY KIDNEY ALLOTRANSPLANTATION, TRANSPLANTATION 2000, 69:737-742. | |
| | FH | J. SOUSA, A. ABIZAID, A. ABIZAID, F. FERES, I. PINTO, A. SEIXAS, R. STAICO, L. MATTOS, A. SOUSA, R. FALOTICO, J. JAEGER, J. POPMA, P. SERRUYS, M. COSTA, LACK OF NEOINTIMAL PROLIFERATION AFTER IMPLANTATION OF SIROLIMUS-COATED STENTS IN HUMAN CORONARY ARTERIES, CIRCULATION 2000, 102:r54-r57. | |
| | FI | C. GREGORY, S. KATZNELSON, S. GRIFFEY, A. KYLES and E. BERRYMAN, FLUVASTATIN IN COMBINATION WITH RAD SIGNICANTLY REDUCES GRAFT VASCULAR DISEASE IN RAT CARDIAC ALLOGRAFTS, CIRCULATION 2001, 72:989-993. | |
| | FJ | R. MORRIS, IMMUNOPHARMACOLOGY OF NEW XENOBIOTIC IMMUNOSUPPRESSIVE MOLECULES, SEMINARS IN NEPHROLOGY 1992, 12:304-314. | |
| | FK | J. MEHILLI, A. KASTRATI, W. KOCH, C. BOTTIGER, N. VON BECKERATH, A. SCHOMIG, RELATION BETWEEN TUMOR NECROSIS FACTOR (TNF) GENE POLYMORPHISMS AND THROMBOTIC EVENTS AND RESTENOSIS IN PATIENTS WITH CORONARY STENTING, ABSTRACT FROM ACCIS 2000 MEETING, 13A. | |
| B | FL | R. KNIGHT, M. FERRARESSO, F. SERINO, S. KATZ, R. LEWIS, AND B.D. KAHAN, LOW-DOSE RAPAMYCIN POTENTIATES THE EFFECTS OF SUBTHERAPEUTIC DOSES OF CYCLOSPORINE TO PROLONG RENAL ALLOGRAFT SURVIVAL IN THE MONGREL CANINE MODEL, TRANSPLANTATION 1993, 55:947-949. | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/30/04 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|---------------------------------------|--|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor S. JAYARAMAN | |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 6 | of | 8 | Attorney Docket Number 795-A03-004 | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials [*] | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| B P | FM | H SCHUURMAN, S COTTENS, S FUCHS, J JOERGENSEN, T MEERLOO, R SEDRANI, M TANNER, G ZENKE and W SCHULER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:32-35. | |
| | FN | B KAHAN, M MURGIA, J SLATION, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675. | |
| | FO | R YATSCOFF, P WANG, K CHAN, D HICKS and J ZIMMERMAN, RAPAMYCIN: DISTRIBUTION, PHARMACOKINETICS, AND THERAPEUTIC RANGE INVESTIGATIONS, THERAPEUTIC DRUG MONITORING 1995, 17:666-671. | |
| | FP | H.U. SCHORLEMMER, F.R. SEILER, and R.R. BARTLETT, PROLONGATION OF ALLOGENEIC TRANSPLANTATION SKIN GRAFTS AND INDUCTION OF TOLERANCE BY LEFLUNOMIDE, A NEW IMMUNOSUPPRESSIVE ISOXAZOL DERIVATIVE, TRANSPLANTATIONS PROCEEDINGS 1993, 25:753-767. | |
| | FQ | D BRANISTEANU, C MATHIEU, R BOUILLON, SYNERGISM BETWEEN SIROLIMUS AND 1,25 DIHYDROXYVITAMIN D, IN VITRO AND IN VIVO, JOURNAL OF NEUROIMMUNOLOGY 1979, 79:138-147. | |
| | FR | B KAHAN, EFFICACY OF SIROLIMUS COMPARED WITH AZATHIOPRINE FOR REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION: A RANDOMISED MULTICENTRE STUDY, LANCET 2000, 356:194-202. | |
| | FS | B KLUGHERZ, G LLANOS, W LIEUALLAN, G KOPLA, G PAPANDREOU, P NARAYAN, T LEVENGOOD, B SASSEEN, S ADELMAN, R FALOTICO, R WILENEIR, STENT-BASED DELIVERY OF SIROLIMUS FOR THE PREVENTION OF RESTENOSIS, ABSTRACT FROM ACCIS 2000 MEETING. | |
| | FT | R SAUNDERS, M METCALFE, M NICHOLSON, RAPAMYCIN IN TRANSPLANTATION: A REVIEW OF EVIDENCE, KIDNEY INTERNATIONAL 2001, 59:3-16. | |
| | FU | R YATSCOFF, D LeGATT, and N KNETEMAN, THERAPEUTIC MONITORING OF RAPAMYCIN: A NEW IMMUNOSUPPRESSIVE DRUG, THERAPEUTIC DRUG MONITORING 1993, 15:478-482. | |
| | FV | S STEPKOWSKI, K NAPOLI, M WANG, X QU, T CHOU, and B KAHAN, EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS, TRANSPLANTATION 1996, 62:986-994. | |
| B P | FW | B. HAUSEN, J. GUMMERT, G.J. BERRY, U. CHRISTIANS, N. SERKOVA, T. IKONEN, L. HOOK, F. LEGAY, W. SCHULER, M.H. SCHREIER, and R.E. MORRIS, PREVENTION OF ACUTE ALLOGRAFT REJECTION IN NONHUMAN PRIMATE LUNG TRANSPLANT RECIPIENTS, TRANSPLANTATION 2000, 69:468-496. | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/30/04 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

| | | | |
|---|---|--------------------------|--------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | |
| | | Filing Date | |
| | | First Named Inventor | S. JAYARAMAN |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet | 7 | of | 8 |
| | | Attorney Docket Number | 795-A03-004 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials ² | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| B | FX | S SEHGAL, RAPAMUNE (SIROLIMUS, RAPAMYCIN): AN OVERVIEW AND MECHANISM OF ACTION, THERAPEUTIC DRUG MONITORING 1995, 17:660-665. | |
| | FY | R MORRIS, MECHANISMS OF ACTION OF NEW IMMUNOSUPPRESSIVE DRUGS, THERAPEUTIC DRUG MONITORING 1995, 17:564-569. | |
| | FZ | P KELLY, S GRUBER, F BEHBOD, and B KAHAN, SIROLIMUS, A NEW, POTENT IMMUNOSUPPRESSIVE AGENT, PHARMACOTHERAPY 1997, 17:1148-1156. | |
| | EA | G INGLE, T STEVENS, and C HOLT, SIROLIMUS: CONTINUING THE EVOLUTION OF TRANSPLANT IMMUNOSUPPRESSION, THE ANNALS OF PHARMACOTHERAPY 2000, 34:1044-1055. | |
| | EB | S MARX, A MARKS, BENCH TO BEDSIDE. THE DEVELOPMENT OF RAPAMYCIN AND ITS APPLICATION OF STENT RESTENOSIS, CIRCULATION 2001, 104:852-855. | |
| | EC | S.M. STEPKOWSKI and B.D. KAHAN, SYNERGISTIC ACTIVITY OF THE TRIPLE COMBINATION: CYCLOSPORINE, RAPAMYCIN, AND BREQUINAR, TRANSPLANTATION PROCEEDINGS 1993, 24:29-31. | |
| | ED | B KAHAN, M MURGIA, J SLATON, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675. | |
| | EE | S SEHGAL, RAPAMUNE (RAPA, RAPAMYCIN, SIROLIMUS): MECHANISM OF ACTION IMMUNOSUPPRESSIVE EFFECT RESULTS FROM BLOCKADE OF SIGNAL TRANSDUCTION AND INHIBITION OF CELL CYCLE PROGRESSION, CLINICAL BIOCHEMISTRY 1998, 31:335-351. | |
| | EF | B KAHAN, J CHANG, S SEHGAL, PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCIN, TRANSPLANTATION 1991, 52:185-191. | |
| | EG | O VILICKY, H ZOU, V MULLER, J LACHA, A SZABO and U HEEMANN, SDZ-RAD PREVENTS MANIFESTATION OF CHRONIC REJECTION IN RAT RENAL ALLOGRAFTS, TRANSPLANTATION 2000, 69:497-502. | |
| B | EH | K NAPOLI AND B KAHAN, HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY OF RAPAMYCIN, CLINICAL CHEMISTRY 1991, 37:294-295. | |

| | |
|--------------------|-------------------------|
| Examiner Signature | Date Considered 9/30/04 |
|--------------------|-------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|--|--|------------------------------------|--|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | |
| | | | Filing Date | |
| | | | First Named Inventor S. JAYARAMAN | |
| | | | Group Art Unit | |
| | | | Examiner Name | |
| Sheet 8 of 8 | | | Attorney Docket Number 795-A03-004 | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| B | EI | Henderson, D.J., I. Naya, R. V. Bundick, G.M. Smith and G. A. Schmidt. 1991. Comparison of the effects of FK-506, Cyclosporin-A, and rapamycin on IL-2 production. Immunology 73: 316. | |
| | EJ | Vathsala, A., T.C. Chou, B.D. Kahan. 1990. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. Transplantation 49: 463. | |
| | EK | Kahan B.D., S. Gibbons, N. Tejpal, S.M. Stepkowski, and T.C. Chou. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51: 232. | |
| | EL | Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177. | |
| | EM | Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922. | |
| | EN | Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation 1993; 56: 1293. | |
| | EO | Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995; 59: 655-661. | |
| | EP | Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of cell cycle. Circulation, 1999; 99: 2164-2170. | |
| | EQ | REDDY, KR, Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs, The Annals of Pharmacotherapy, Vol 34, pp 915-923, July/August 2000 | |
| | ER | M. GUBA et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nature Medicine, Volume 8, February 2002, pp 128-135. | |
| ES | M. IURLARO et al., Antiangiogenesis by cyclosporine, Experimental Hematology, Volume 26, 1998, pp. 1215-1222. | | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/30/04 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐


PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|----|---|------------------------|-----------------------------------|-------------|
| Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | | | |
| | | | | Application Number | |
| | | | | Filing Date | |
| | | | | First Named Inventor S. Jayaramna | |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet 3 | of | 8 | Attorney Docket Number | | 795-A03-004 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|-----------------------------|-----------------------------------|---|--|---|
| Examiner Initials | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | BR | 6,258,121 | | Yang et al. | 07-10-2001 | |
| | BS | 6,273,913 | | Wright et al. | 08-14-2001 | |
| | BT | 6,299,604 | | Ragheb | 10-09-2001 | |
| | BU | 6,309,380 | | Larson | 10-30-2001 | |
| | BV | 6,335,029 | | Kamath et al. | 01-01-2002 | |
| | BW | 6,344,035 | | Chudzik et al. | 02-05-2002 | |
| | BX | 6,364,903 | | Tseng et al. | 04-02-2002 | |
| | BY | 6,368,658 | | Schwartz et al. | 04-09-2002 | |
| | BZ | 6,379,382 | | Yang | 04-30-2002 | |
| | CA | 6,455,518 | | Zenke et al | 09-24-2002 | |
| | CB | 6,530,951 | | Bates | 03-11-2003 | |
| | CC | 6,545,097 | | Pinchuk | 04-08-2003 | |
| | CD | 6,585,764 | | Wright et al. | 07-01-2003 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|---|---|----------------|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | DA | | WO 98/55162 | A2 | Polybiomed Ltd. | 12-10-1998 | | |
| | DB | | WO 98/18468 | A1 | American Home Products | 05-07-1998 | | |
| | DC | | WO 98/07415 | A2 | Novartis AG | 02-26-1996 | | |
| | DD | | WO 96/04906 | A1 | Wellcome Foundation Ltd. | 02-22-1996 | | |

| | |
|--|-------------------------|
| Examiner  | Date Considered 9/30/04 |
|--|-------------------------|

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.